STOCK TITAN

GT Biopharma Inc. - GTBP STOCK NEWS

Welcome to our dedicated page for GT Biopharma news (Ticker: GTBP), a resource for investors and traders seeking the latest updates and insights on GT Biopharma stock.

GT Biopharma Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel immuno-oncology products targeting cancers such as acute myeloid leukemia, myeloid dysplastic syndrome, and multiple solid tumors. Leveraging its proprietary NK cell engager (TriKE) platform technology, the company is dedicated to advancing innovative therapeutics in the United States. With a primary focus on cancer treatment, GT Biopharma's TriKE platforms offer promising solutions for hematologic malignancies, sarcoma, and solid tumors.

Rhea-AI Summary

GT Biopharma, Inc. (NASDAQ: GTBP) announced the enrollment of Patient 10 in its GTB-3550 TriKE™ Phase I/II clinical trial targeting high-risk myelodysplastic syndromes (MDS) and relapsed acute myeloid leukemia (AML). Dosing for Patient 10 is set at 100mcg/kg/day. Earlier trial results showed a significant 63.7% reduction in bone marrow blast levels and improvements in NK cell function without severe side effects. Currently, the trial aims to establish the maximum tolerated dose and assess NK and T cell functionality.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.75%
Tags
-
Rhea-AI Summary

GT Biopharma announced updated interim Phase I/II clinical trial results for GTB-3550 TriKE™, aimed at treating high-risk myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), during the Innate Killer Summit 2021. Key findings include a 63.7% reduction in bone marrow blasts, with a significant number of patients responding positively. Importantly, no cytokine release syndrome (CRS) was observed, and the treatment does not rely on progenitor-derived therapies. The trial involved 9 patients, and ongoing dose escalation aims to enhance efficacy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.04%
Tags
-
Rhea-AI Summary

GT Biopharma, Inc. (NASDAQ: GTBP) announced updated interim results from its Phase I/II clinical trial of GTB-3550, aimed at treating high-risk myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). The trial involved 9 patients, of whom 60% showed reduced bone marrow blasts, with significant reductions in two patients. Notably, no cases of Cytokine Release Syndrome (CRS) were reported. CEO Anthony Cataldo expressed optimism about the ongoing dose escalation and the potential for GTB-3550 to offer a less expensive alternative to existing therapies. The company’s focus remains on advancing its innovative TriKE technology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.49%
Tags
Rhea-AI Summary

GT Biopharma (NASDAQ: GTBP) will present at the Virtual 33rd Annual Roth Conference on March 17, 2021, at 12:00 p.m. ET. The presentation will cover its innovative Natural Killer (NK) cell engager immunotherapy platform, TriKE™, designed for treating cancers and infectious diseases. The GTB-3550 TriKE™ is in a Phase I/II clinical trial for patients with CD33+ malignancies, showing promising interim results in reducing bone marrow blast levels in AML and MDS patients. A live webcast can be accessed on the company's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.2%
Tags
conferences
-
Rhea-AI Summary

GT Biopharma, Inc. (NASDAQ: GTBP) has announced promising preclinical results for its ROR1 TriKE™ product candidate aimed at treating prostate cancer. ROR1, a receptor overexpressed in various cancers, was targeted using TriKE™ technology to enhance Natural Killer (NK) cell activity. Results showed effective NK cell killing in multiple prostate cancer cell lines, as well as significant NK cell activation and interferon gamma production. The company plans further IND-enabling studies, with the aim to transition to a Phase I/II clinical trial.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.35%
Tags
-
Rhea-AI Summary

GT Biopharma (NASDAQ: GTBP) announced the addition of the University of Wisconsin – Madison Carbone Cancer Center as a second site for its ongoing Phase I/II clinical trial of GTB-3550 TriKE™. This trial targets patients with CD33+ malignancies, including acute myeloid leukemia (AML). The trial aims to evaluate the safety and maximum tolerated dose of GTB-3550 TriKE™. Interim results showed reduction in bone marrow blast levels in AML patients with no reported toxicities. The trial is part of GT Biopharma's effort to advance its NK cell engager immunotherapy platform.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.82%
Tags
Rhea-AI Summary

GT Biopharma, Inc. (NASDAQ: GTBP) announced an expanded GMP manufacturing agreement with Cytovance Biologics to enhance manufacturing of TriKE™ immunotherapy products. This transition positions the company for large-scale production in anticipation of further clinical trials for GTB-3550 TriKE™, targeting Acute Myeloid Leukemia (AML) and Myelodysplastic syndromes (MDS). Interim results indicate GTB-3550 TriKE™ effectively reduces bone marrow blast levels in patients without toxicities. The company aims to initiate additional clinical trials in early 2022, boosting its potential market presence.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.62%
Tags
-
Rhea-AI Summary

GT Biopharma, Inc. (NASDAQ: GTBP) has successfully closed an underwritten public offering of 4,300,000 Units at $5.50 per Unit, raising approximately $23.6M in gross proceeds. The offering includes a 45-day over-allotment option for underwriters to purchase an additional 645,000 Units. Following the offering, GT Biopharma's cash position is about $30M, extending its runway through 2022, and successfully extinguishing over $25M in debt. This financing supports ongoing clinical trials for its TriKE™ platform targeting cancer therapies, particularly for Acute Myeloid Leukemia and Myelodysplastic syndromes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.64%
Tags
-
Rhea-AI Summary

GT Biopharma announced an underwritten public offering of 4,300,000 Units at $5.50 each, expected to close on February 16, 2021. The offering aims to raise approximately $23.6 million before expenses. An over-allotment option allows underwriters to purchase an additional 645,000 Units. Following a 1-for-17 reverse stock split, GT Biopharma's common stock will begin trading on The Nasdaq Capital Market under the ticker symbol GTBP on February 11, 2021. The offering is facilitated by Roth Capital Partners and Dawson James Securities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-39.06%
Tags
Rhea-AI Summary

GT Biopharma has appointed Dr. Greg Berk, M.D. to its Board of Directors. Dr. Berk brings extensive experience in oncology drug development, having previously held senior positions at Verastem, Sideris Pharmaceuticals, and BIND Therapeutics. He is expected to contribute significantly to the advancement of the company's proprietary NK cell engager (TriKE™) technology, particularly in developing its lead candidate, GTB-3550, for treating acute myeloid leukemia (AML). GT Biopharma aims to harness the immune system to combat cancer effectively.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.8%
Tags
management

FAQ

What is the current stock price of GT Biopharma (GTBP)?

The current stock price of GT Biopharma (GTBP) is $2.81 as of December 23, 2024.

What is the market cap of GT Biopharma (GTBP)?

The market cap of GT Biopharma (GTBP) is approximately 6.3M.

What is GT Biopharma Inc. focused on?

GT Biopharma is focused on developing and commercializing novel immuno-oncology products targeting cancers such as acute myeloid leukemia, myeloid dysplastic syndrome, and multiple solid tumors.

What is GT Biopharma's proprietary platform technology?

GT Biopharma leverages its NK cell engager (TriKE) platform technology to develop innovative therapeutics for a varied range of disease areas, with a primary focus on cancer treatment.

What types of cancers does GT Biopharma's TriKE platforms target?

GT Biopharma's TriKE platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.

What stage is GT Biopharma currently in?

GT Biopharma is a clinical-stage biopharmaceutical company, actively engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform.

What sets GT Biopharma apart in the biopharmaceutical industry?

GT Biopharma's innovative TriKE platforms and focus on immuno-oncology products position it as a key player in the development of effective treatments for various types of cancer.

GT Biopharma Inc.

Nasdaq:GTBP

GTBP Rankings

GTBP Stock Data

6.35M
1.96M
12.15%
67.52%
0.79%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SAN FRANCISCO